Milestone Pharmaceuticals Inc. (NASDAQ: MIST) Q1 Earnings Miss: CARDAMYST Launch Begins as Cash Runway Supports Growth Plans

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported first-quarter 2026 results that missed available analyst expectations, while also highlighting early commercial progress for CARDAMYST and a strong liquidity position.

Milestone Pharmaceuticals is an emerging commercial-stage biopharmaceutical company focused on developing and commercializing cardiovascular medicines. Its lead product, CARDAMYST, also known as etripamil nasal spray, is approved by the U.S. Food and Drug Administration for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults.

On May 13, 2026, Milestone announced financial results for the first quarter ended March 31, 2026. The company reported a net loss of $26.1 million, or $0.20 per share, compared with a net loss of $20.8 million, or $0.31 per share, in the same quarter a year earlier. Although the per-share loss improved year over year, the net loss widened because of higher commercial spending related to the CARDAMYST launch.

Revenue for the quarter was $238,000. This revenue primarily reflected early product sales from CARDAMYST following its commercial launch. MarketBeat listed expected revenue of $30.12 million, implying a significant revenue miss, though investors should note that consensus estimates for a newly launched biotech product can vary across data providers.

Operationally, Milestone reported early progress with CARDAMYST. The company said promotional launch activities began in mid-February 2026 with a 60-person national sales force. Through April, approximately 600 prescriptions had been filled for about 560 patients, and roughly 400 unique prescribers had started patients on CARDAMYST.

The company also secured national formulary coverage with Express Scripts, effective March 27, 2026. Milestone said that more than 25% of commercially insured lives in the United States now have coverage for CARDAMYST, an important early step toward broader patient access.

Milestone is also advancing etripamil for atrial fibrillation with rapid ventricular rate, or AFib-RVR. The company has initiated a Phase 3 registrational program and expects to enroll the first patient in the second half of 2026.

Despite the earnings and revenue miss, Milestone maintains a strong liquidity position. As of March 31, 2026, the company had $184.2 million in cash, cash equivalents, and short-term investments, compared with $106.0 million at the end of 2025. Management expects this capital to fund operations into the second half of 2027, including commercial launch activities and the AFib-RVR Phase 3 trial.

From a balance-sheet perspective, Milestone’s current ratio of about 9.18 is accurate. The company reported current assets of $192.3 million and current liabilities of $20.9 million as of March 31, 2026, indicating substantial short-term liquidity.